Advances in malignant peritoneal mesothelioma

International Journal of Colorectal Disease

Volumn 30, Issue 1, 2015, Pages 1-10

  Cao, Shoubo ^a   Jin, Shi ^a   Cao, Jingyan ^a   Shen, Jing ^a   Hu, Jing ^a   Che, Dehai ^a   Pan, Bo ^a   Zhang, Jiawen ^a   He, Xiaoxi ^a   Ding, Dian ^a   Gu, Feifei ^a   Yu, Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

CRS; Diagnosis; HIPEC; Management; MPM

Indexed keywords

ASBESTOS; CISPLATIN; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 6; MESOTHELIN; PEMETREXED; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PERITONEUM MESOTHELIOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIMIAN VIRUS 40; TUBERCULOUS PERITONITIS; FEMALE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; PERITONEAL NEOPLASMS; PROGNOSIS;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; PERITONEAL NEOPLASMS; PROGNOSIS;

EID: 84926685887     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-014-2029-1     Document Type: Review

References (85)

1. Sharma H, Bell I, Schofield J et al (2011) Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepathol Gastroenterol 35: 55-59
2. Carbone M, Ly BH, Dodson RF et al (2012) Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 227: 44-58
3. Moore AJ, Parker RJ, Wiggins J (2008) Malignant mesothelioma. Orphanet J Rare Dis 3: 34
4. Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603
5. Roe OD, Creaney J, Lundgren S et al (2008) Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 61: 235-243
6. Garcia-Carbonero R, Paz-Ares L (2006) Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 32: 676-681
7. De Pangher Manzini V (2005) Malignant peritoneal mesothelioma. Tumori 91: 1-5
8. Wagner JC, Sleegs CA, Marchand P (1960) Diffuse pleural mesothelioma. Br J Ind Med 17: 260-271
9. Tan GH, Cheung M, Chanyaputhipong J et al (2013) Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore 42: 291-296
10. Mirarabshahii P, Pillai K, Chua TC et al (2012) Diffuse malignant peritoneal mesothelioma-an update on treatment. Cancer Treat Rev 38: 605-612
11. Magge D, Zenati MS, Austin F et al (2014) Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 21: 1159-1165
12. Baratti D, Kusamura S, Cabras AD et al (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49: 3140-3148
13. Chua TC, Yan TD, Morris DL (2009) Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 99: 109-113
14. Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27: 6237-6242
15. Goslin B, Sevak S, Siripong A et al (2012) Outcomes of cytoreduction with hyperthermic intraperitoneal chemotherapy: our experience at a midwest community hospital. Am J Surg 203: 383-386
16. Miller J, Wynn H (1908) A malignant tumor arising from the endothelium of the peritoneum and producing a mucoid ascitic fluid. J Pathol Bacteriol 12: 267
17. Marinaccio A, Montanaro F, Mastrantonio Met al (2005) Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-periodcohort models. Int J Cancer 115: 142-147
18. Gogou E, Kerenidi T, Chamos Vet al (2009)Mesothelioma mortality in Greece from 1983 to 2003. Int J Clin Pract 63: 944-948
19. Myojin T, Azuma K, Okumura J et al (2012) Future trends of mesothelioma mortality in Japan based on a risk function. Ind Health 50: 197-204
20. Schonfeld SJ, McCormack V, Rutherford MJ et al (2014) Regional variations in German mesothelioma mortality rates: 2000-2010. Cancer Causes Control 25: 615-624
21. Hodgson JT, McElvenny DM, Darnton AJ et al (2005) The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92: 587-593
22. Pitarque S, Clèries R, Martínez JM et al (2008) Mesothelioma mortality in men: trends during 1977-2001 and projections for 2002-2016 in Spain. Occup Environ Med 65: 279-282
23. Banaei A, Auvert B, Goldberg M et al (2000) Future trends in mortality of French men from mesothelioma. Occup Environ Med 57: 488-494
24. Leigh J, Davidson P, Hendrie L et al (2002) Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 41: 188-201
25. Price B, Ware A (2004)Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 159: 107-112
26. Naka H, Naka A (1984) Clinicopathological study on 100 Japanese patients with peritoneal mesothelioma in Japan. Gan No Rinsho 30: 1-10
27. Metintas M, Hillerdal G, Metintas S (1999)Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J 13: 523-526
28. Stey C, Landolt-Weber U, Vetter Wet al (1995)Malignant peritoneal mesothelioma after Thorotrast exposure. Am J Clin Oncol 18: 313-317
29. Weissmann LB, Corson JM, Neugut AI et al (1996) Malignant mesothelioma following treatment for Hodgkin's disease. J Clin Oncol 14: 2098-2100
30. Shivapurkar N, Wiethege T, Wistuba II et al (1999) Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem 76: 181-188
31. Acherman YI, Welch LS, Bromley CM et al (2003) Clinical presentation of peritoneal mesothelioma. Tumori 89: 269-273
32. Manzini Vde P, Recchia L, Cafferata M et al (2010) Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 21: 348-353
33. Cao SB, Jin S, Cao JY et al (2014) Colonic invasion induced by malignant peritoneal mesothelioma. Int J Colorectal Dis 29: 891-892
34. Munkholm-Larsen S, Cao CQ, Yan TD (2009) Malignant peritoneal mesothelioma. World J Gastrointest Surg 1: 38-48
35. Tabata C, Kanemura S, Tabata R et al (2013) Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 47: 684-688
36. Park JY, Kim KW, Kwon HJ et al (2008) Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 191: 814-825
37. Nagata S, Tomoeda M, Kubo C et al (2011)Malignant mesothelioma of the peritoneum invading the liver and mimicking metastatic carcinoma: a case report. Pathol Res Pract 207: 395-398
38. Daskalogiannaki M, Prassopoulos P, Raissaki M et al (2000) Malignant peritoneal mesothelioma presenting with respiratory symptoms. Eur Radiol 10: 814-816
39. Heatley MK (2004) Sister Mary Joseph's nodule in malignant mesothelioma. Histopathology 45: 299-300
40. Haliloglu M, Hoffer FA, Fletcher BD (2000) Malignant peritoneal mesothelioma in two pediatric patients: MR imaging findings. Pediatr Radiol 30: 251-255
41. Yamamuro M, Gerbaudo VH, Gill RR et al (2007) Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol 64: 356-366
42. Cao Q, Lu M, Heath J et al (2012) F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma. Clin Nucl Med 37: 492-494
43. Iversen LH, Rasmussen PC, Laurberg S (2013) Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 100: 285-292
44. Wang J, Gao L, Tang S et al (2013) A retrospective analysis on the diagnostic value of ultrasound-guided percutaneous biopsy for peritoneal lesions. World J Surg Oncol 11: 251
45. Marchevsky AM (2008) Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 132: 397-401
46. Suster S, Moran CA (2006) Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol 13: 316-329
47. Taşkín S, Gümüş Y, Kiremitçi S et al (2012) Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features. Int J Clin Exp Pathol 5: 472-478
48. Laury AR, Hornick JL, Perets R et al (2010) PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 34: 627-635
49. Krasuski P, Poniecka A, Gal E (2002) The diagnostic challenge of peritoneal mesothelioma. Arch Gynecol Obstet 266: 130-132
50. Chen LY, Huang LX, Wang J et al (2011) Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B 12: 381-384
51. Rogoff EE, Hilaris BS, Huvos AG (1973) Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer 32: 656-664
52. Cain J, Nori D, Huvos A et al (1983) The role of radioactive colloids in malignant peritoneal mesothelioma. Gynecol Oncol 16: 263-274
53. Lederman GS, Recht A, Herman Tet al (1987) Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer 59: 1882-1886
54. Hesdorffer ME, Chabot JA, Keohan ML et al (2008) Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 31: 49-54
55. Takeuchi K, Fujimoto M, Tsujino Tet al (2007) Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel. Eur J Gynaecol Oncol 28: 322-323
56. Turner K, Varghese S, Alexander HR Jr (2012) Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Cancer Netw 10: 49-57
57. O'Brien ME, Watkins D, Ryan C et al (2006) A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17: 270-275
58. Simon GR, Verschraegen CF, Jänne PA et al (2008) Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 26: 3567-3572
59. Verschraegen CF (2001) Intracavitary therapies for mesothelioma. Curr Treat Options Oncol 2: 385-394
60. Leinwand JC, Zhao B, Guo X et al (2013) Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy. Ann Surg Oncol 20: S553-S559
61. Cameron RB, Hou D (2013) Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation. J Thorac Cardiovasc Surg 145: 496-504
62. Sebbag G, Yan H, Shmookler BM et al (2000) Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 87: 1587-1593
63. Deraco M, Nonaka D, Baratti D et al (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13: 229-237
64. Teo MC, Tan GH, Tham CK et al (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. Ann Surg Oncol 20: 2968-2974
65. Alexander HR Jr, Bartlett DL, Pingpank JF et al (2013) Treatment factors associated with long-term survival following cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153: 779-78666.
66. Haslinger M, Francescutti V, Attwood K et al (2013) A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Med 2: 334-342
67. Levine EA, Stewart JH 4th, Shen P et al (2014) Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1, 000 patients. J Am Coll Surg 218: 573-587
68. Feldman AL, Libutti SK, Pingpank JF et al (2003)Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21: 4560-4567
69. Alexander HR Jr (2010) Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol 17: 21-22
70. Los G, Smals OA, van Vugt MJ et al (1992) A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 52: 1252-1258
71. Randle RW, Swett KR, Swords DS et al (2014) Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 21: 1474-1479
72. Votanopoulos KI, Ihemelandu C, Shen P et al (2012) Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg 215: 412-417
73. Chua TC, Quinn LE, Zhao J et al (2013) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. J Surg Oncol 108: 81-88
74. Soulié P, Ruffié P, Trandafir L et al (1996) Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 14: 878-885
75. Bielefeldt-Ohmann H, Marzo AL, Himbeck RP et al (1995) Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother 40: 241-250
76. Tani M, Tanimura H, Yamaue H et al (1998) Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases. Surg Today 28: 647-651
77. Hegmans JP, Hemmes A, Aerts JG et al (2005) Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 171: 1168-1177
78. Ho M, Feng M, Fisher RJ et al (2011) A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 128: 2020-2030
79. Govindan R, Kratzke RA, Herndon JE 2nd et al (2005) Gefitinib in patients withmalignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11: 2300-2304
80. Yan TD, Brun EA, Cerruto CA et al (2007) Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 14: 41-49
81. Cao C, Yan TD, Deraco M et al (2012) Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 23: 1494-1498
82. Wolf AS, Richards WG, Tilleman TR et al (2010) Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg 90: 949-956
83. Pillai K, Pourgholami MH, Chua TC et al (2013)Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 139: 987-994
84. Yan TD, Yoo D, Sugarbaker PH (2006) Significance of lymph node metastasis in patients with malignant peritoneal mesothelioma. Eur J Surg Oncol 32: 948-953
85. Baratti D, Kusamura S, Cabras AD et al (2010) Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 17: 45-53